IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-Small cell lung cancer cells

Haibo Lu, Li Wang, Wen Gao, Jieru Meng, Bingbing Dai, Shuhong Wu, John Minna, Jack A. Roth, Wayne L. Hofstetter, Stephen G. Swisher, Bingliang Fang

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Insulin-like growth factor (IGF)-binding protein-2 (IGFBP2) expression is increased in various types of cancers, including in a subset of patients with lung cancer. Because IGFBP2 is involved in signal transduction of some critical cancer-related pathways, we analyzed the association between IGFBP2 and response to pathwaytargeted agents in sevenhumannon-small cell lung cancer (NSCLC) cell lines. Western blot analysis and ELISA showed that four of the seven NSCLC cell lines analyzed expressed high levels of IGFBP2, whereas the remaining three had barely detectable IGFBP2. Susceptibilities of those seven cell lines to nine anticancer agents targeting to IGF1R, Src, FAK, MEK, and AKT were determined by a dose-dependent cell viability assay. The results showed that high IGFBP2 levels were associated with resistance to dasatinib and, to a lesser degree, to sacaratinib, but not to other agents. Ectopic IGFBP2 overexpression or knockdown revealed that changing IGFBP2 expression levels reversed dasatinib susceptibility phenotype, suggesting a causal relationship between IGFBP2 expression and dasatinib resistance. Molecular characterization revealed that focal adhesion kinase (FAK) activation was associated with increased IGFBP2 expression and partially contributed to IGFBP2- mediated dasatinib resistance. Treatment with a combination of dasatinib and FAK inhibitor led to enhanced antitumor activity in IGFBP2-overexpressing and dasatinib-resistant NSCLC cells in vitro and in vivo. Our results showed that the IGFBP2/FAK pathway is causally associated with dasatinib resistance andmaybe used as biomarkers for identification of dasatinib responders among patients with lung cancer. Simultaneous targeting on Src and FAK will likely improve the therapeutic efficacy of dasatinib for treatment of lung cancer. Mol Cancer Ther; 12(12); 2864-73.

Original languageEnglish (US)
Pages (from-to)2864-2873
Number of pages10
JournalMolecular Cancer Therapeutics
Issue number12
StatePublished - Dec 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-Small cell lung cancer cells'. Together they form a unique fingerprint.

Cite this